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THE DEVELOPMENT of de novo malignancies inkidney transplant recipients represents a major prob-
lem. The reported prevalence is between 1% and 16% in
Western countries and 1% to 3% in Asian countries.1–3 In
our Center, the overall prevalence of 7.13% was reported in
1997 by Arnaldo et al.4 The most prevalent cancers are
squamous cell carcinomas and basal cell carcinomas of the
skin with an increasing cumulative incidence with longer
survival of the patient.5,6 Epidemiological data show several
risk factors, including pigmentary characteristics, solar irra-
diation, viral warts, type and doses of long-term immuno-
suppressants, presence of an oncogenic virus (Epstein-
Barr), with age, with time of dialysis, genetic factors and
diabetes among other considerations. The posttransplanta-
tion lymphoproliferative diseases, lymphoma, and Kaposi’s
sarcoma are associated with the immunosuppressive ther-
apy and oncogenic viruses.7–9 Type 2 diabetes mellitus
(DM2) has been related to the risk for colon, endometrial,
pancreatic, and hepatic cancers as well as an increased risk
of non-Hodgkin’s lymphoma. Until now there are no re-
ports of similar correlations with type 1 diabetes mellitus
(DM1).10–12 Posttransplantation diabetes mellitus is in
some ways similar to DM2, including insulin resistance and
the presence of an overweight or obesity situation, but there
are no reports on the prevalence of malignancy in this
group of patients. The aim of this study was to determine
the prevalence of malignancy during follow-up of all pa-
tients with diabetes bearing a kidney transplant in our
Center.
PATIENTS AND METHODS
Between 1992 and 2001, 1070 patients underwent transplantation
with a kidney including, 55 (5.6%) diabetics: 33 with DM1, 22 with
DM2, and 109 (10.4%) with posttransplantation diabetes (PTDM).
We reviewed the files of these patients and performed statistical
analyses using mean and SD values with the chi-square test.
RESULTS
We observed nine cases of malignancies (5.6%), namely six
men and three women. Two patients had DM1 (6.1%), one
patient had DM2 (4.5%), and six patients had PTDM
(5.7%). The types of cancer, included single cases of
multiple myeloma, non-Hodgkin’s lymphoma, melanoma,
skin basal cell cancer, breast cancer, laryngeal cancer, and
lung small-cells cancer as well as two cases of skin squamous
cell cancer (Table 1). The mean age at diagnosis was 49.2
years (range: 28 to 63 years), the mean duration of the
kidney transplant was 58.7 months (range: 27 to 108
months), although in seven cases it occurred at more than
36 months. The mean creatininemia at diagnosis was 1.1
mg/dL (range: 0.8 to 2 mg/dL). The immunosuppressive
therapy was a triple-regimen in 66.6% of patients using
azathioprine or mycophenolate together with oral methyl-
prednisolone and cyclosporine. In 33.3% of patients it was
double-therapy with methylprednisolone and cyclosporine.
The follow-up revealed four deaths. Among the five living
patients, two have returned to dialysis and three have
functioning grafts.
DISCUSSION
The causes of cancer are multifactorial. Several risk factors
have been reported, including type and cumulative dose of
immunosuppressive agents, age, sex, duration of dialysis,
smoking, obesity, sunlight exposure, oncogenic virus
(EBNA, cytomegalovirus), diabetes, world region and ge-
netic factors. The prevalence in our patients was 5.6%, a
rate similar to other reports. The risk increased after 36
months posttransplantation. Reduction in immunosuppres-
sion was performed in all patients; some returned to
dialysis. This posttransplantation complication shows a high
mortality rate and poses problems with immunosuppres-
sion.7 Tumors diagnosed before 100 days after transplanta-
tion may be viewed as previously existent or possibly
donor-transmitted malignancies, a particular problem with
older cadaveric donors. We must be alert for the potential
risk of donor-transmited malignancies, which are associated
with a high incidence of disseminated disease and mortality
in recipients.13 The outcome of a malignancy depends on
several factors: the type of cancer, the time of diagnosis and
the delay to therapy. Early diagnosis and treatment are
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essential for a satisfactory outcome, so a regular screening
examination is recommended for all patients bearing a
kidney transplant.14
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Table 1. Patients with Diabetes Who Underwent Kidney Transplantation and Malignancies
Cases Sex Age (y) Type of Diabetes Malignancy Treatment Outcome
1 F 48 PTDM Lung small cell Chemotherapy Dead after 6 mo with functioning TX
2 F 50 PTDM Multiple myeloma Chemotherapy Dead in 3 mo with functioning TX
3 M 61 PTDM Non-Hodgkin’s lymphoma Radiotherapy Dead after 48 mo with functioning TX
4 M 63 PTDM Skin squamous cell Surgery radiotherapy Alive with nonfunctioning TX
5 M 59 PTDM Skin squamous cell Surgery Alive with functioning TX
6 M 38 PTDM Skin basal cell Surgery Alive with nonfunctioning TX
7 F 28 DM1 Breast Surgery Alive with functioning TX
8 M 43 DM1 Laryngeal Surgery radiotherapy Alive with functioning TX
9 M 53 DM2 Melanoma Surgery Dead after 11 mo with functioning TX
Abbreviations: F, female; M, male.
KIDNEY TRANSPLANTATION AND DIABETES 1099
